Pharmaceutical giant Eli Lilly & Co. has unveiled a pair of major strategic initiatives within a single day, signaling a significant acceleration of its growth ambitions. The company announced the acquisition of Orna Therapeutics and a substantially expanded collaboration with Innovent Biologics, directing billions of dollars toward strengthening its position in next-generation biotechnology, particularly within immunology and oncology.
This dual announcement underscores a strategic pivot for Lilly. The deal for Orna Therapeutics involves a total potential consideration of up to $2.4 billion. The central attraction is Orna’s proprietary in vivo CAR-T technology platform. Its lead candidate, ORN-252, which targets CD19 for B-cell autoimmune diseases, is positioned near the start of clinical trials.
Deepened Alliance with Innovent Unlocks Billions More
Concurrently, Eli Lilly has significantly deepened its established partnership with Innovent Biologics. This renewed strategic collaboration will focus on developing and commercializing oncology and immunology treatments. As part of the agreement, Innovent will receive an upfront payment of $350 million. The deal also includes potential development, regulatory, and commercial milestone payments that could total approximately $8.5 billion.
The division of responsibilities is clearly defined: Innovent will lead development activities in China through clinical proof-of-concept, while Lilly secures exclusive rights to commercialize any resulting products outside of Greater China.
Robust Financial Performance Fuels Ambition
This aggressive expansion strategy is built upon a foundation of strong recent financial results. Just last week, Lilly reported fourth-quarter 2025 revenue of $19.29 billion, representing a year-over-year increase of 42.6%. Looking ahead, the company has provided full-year 2026 revenue guidance in the range of $80 to $83 billion.
Should investors sell immediately? Or is it worth buying Eli Lilly?
Key Transaction and Financial Details:
- Orna Therapeutics Acquisition: Potential value up to $2.4 billion; centers on in vivo CAR-T platform (lead candidate ORN-252).
- Innovent Biologics Collaboration: $350 million upfront payment; potential milestone payments of ~$8.5 billion.
- 2026 Revenue Forecast: $80 billion to $83 billion.
- Analyst Action: Deutsche Bank raised its price target to $1,285 per share.
Market Analysts Respond Positively
Market experts have reacted swiftly to the news. Deutsche Bank reaffirmed its Buy rating on Eli Lilly shares and increased its price target from $1,200 to $1,285. This follows a recent move by JPMorgan, which on February 5 raised its target to $1,300, citing the company’s dominant standing in the metabolic disease market despite growing competition.
While the new deals target immunology and oncology, Lilly’s metabolic franchise remains its primary growth engine. In Q4 2025 alone, the obesity drug Zepbound generated $4.26 billion in revenue, surpassing sales of Novo Nordisk’s Wegovy. CEO David Ricks recently highlighted that the expected Medicare coverage for anti-obesity medications starting in 2026 should provide an additional boost to volume growth.
Through these two transactions, Eli Lilly is strategically diversifying its development pipeline beyond its current core business. The combination of a powerful financial position and this strategic repositioning is likely to provide the company with substantial additional runway for future expansion.
Ad
Eli Lilly Stock: Buy or Sell?! New Eli Lilly Analysis from February 10 delivers the answer:
The latest Eli Lilly figures speak for themselves: Urgent action needed for Eli Lilly investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 10.
Eli Lilly: Buy or sell? Read more here...
